{"product_id":"starns-business-model-canvas","title":"Strides Pharma Science Limited (STAR.NS): Canvas Business Model","description":"\u003cp\u003eDiscover the dynamic world of Strides Pharma Science Limited as we dive into their innovative Business Model Canvas. This comprehensive framework reveals how they leverage strategic partnerships, cutting-edge manufacturing, and a commitment to quality to deliver affordable medications across global markets. From diverse customer segments to robust revenue streams, explore the intricate business strategies that drive their success in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited has established a range of key partnerships that facilitate its operational effectiveness and market reach.\u003c\/p\u003e\n\n\u003ch3\u003eStrategic alliances with raw material suppliers\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma relies heavily on strategic alliances with raw material suppliers to ensure a consistent supply of high-quality ingredients for its pharmaceutical products. As of fiscal year 2023, Strides reported a significant increase in procurement efficiency through these partnerships, leading to a reduction in raw material costs by \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous year. The company has formed alliances with over \u003cstrong\u003e50\u003c\/strong\u003e suppliers across various geographical locations, which enhances its ability to maintain supply chain resilience.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborations with research institutions\u003c\/h3\u003e\n\n\u003cp\u003eResearch collaborations play a crucial role in the innovative capabilities of Strides Pharma. The company has partnered with renowned institutions such as the Indian Institute of Science (IISc) and various international universities to foster R\u0026amp;D initiatives. In the past year, Strides invested approximately \u003cstrong\u003eINR 150 million\u003c\/strong\u003e in joint research projects aimed at developing niche therapeutic areas. These collaborations have resulted in the filing of \u003cstrong\u003e10\u003c\/strong\u003e new patents, enhancing Strides’ portfolio and competitive position in the market.\u003c\/p\u003e\n\n\u003ch3\u003ePartnerships with distribution networks\u003c\/h3\u003e\n\n\u003cp\u003eTo broaden its market presence, Strides has formed strategic partnerships with key distribution networks. The company has established collaborations with both domestic and international distributors, including major players like Mylan and Teva Pharmaceuticals. In fiscal year 2023, Strides’ distribution partnerships contributed to a revenue of approximately \u003cstrong\u003eINR 18 billion\u003c\/strong\u003e, representing a growth of \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year. These partnerships enable Strides to reach over \u003cstrong\u003e100\u003c\/strong\u003e countries and enhance its global footprint.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eKey Partners\u003c\/th\u003e\n        \u003cth\u003eInvestment (INR millions)\u003c\/th\u003e\n        \u003cth\u003eOutcomes\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n        \u003ctd\u003e50+ suppliers globally\u003c\/td\u003e\n        \u003ctd\u003eUnknown\u003c\/td\u003e\n        \u003ctd\u003e15% reduction in material costs\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003eIISc, International Universities\u003c\/td\u003e\n        \u003ctd\u003e150\u003c\/td\u003e\n        \u003ctd\u003e10 new patents filed\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Networks\u003c\/td\u003e\n        \u003ctd\u003eMylan, Teva Pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eUnknown\u003c\/td\u003e\n        \u003ctd\u003e18 billion in revenue, 12% growth YoY\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these strategic partnerships, Strides Pharma Science Limited successfully mitigates risks, enhances resource acquisition, and strengthens its operational capabilities in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrides Pharma Science Limited\u003c\/strong\u003e engages in several key activities that are essential for delivering its value proposition in the pharmaceutical sector. These activities include pharmaceutical manufacturing, research and development, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturing\u003c\/h3\u003e\n\n\u003cp\u003eStrides operates multiple manufacturing facilities that adhere to stringent quality standards. As of October 2023, Strides has \u003cstrong\u003efive manufacturing plants\u003c\/strong\u003e across India, the United States, and Africa. The company reported a capacity of more than \u003cstrong\u003e1.5 billion units\u003c\/strong\u003e annually, producing a wide variety of dosage forms including tablets, capsules, and injectable formulations.\u003c\/p\u003e\n\n\u003cp\u003eIn the fiscal year ending March 2023, Strides' revenue from manufacturing stood at approximately \u003cstrong\u003eINR 1,477 crore\u003c\/strong\u003e, representing a growth of \u003cstrong\u003e10%\u003c\/strong\u003e year-on-year. The company focuses on high-margin products and has recently expanded its portfolio with biosimilars and complex generics, contributing to its competitive edge in the market.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\n\u003cp\u003eResearch and development (R\u0026amp;D) is a cornerstone of Strides' operations. The company invests heavily in R\u0026amp;D to innovate and enhance product offerings. For FY 2023, Strides allocated around \u003cstrong\u003e6% of its total revenue\u003c\/strong\u003e to R\u0026amp;D activities, amounting to approximately \u003cstrong\u003eINR 88 crore\u003c\/strong\u003e. This investment supports the development of new formulations and strengthens its pipeline.\u003c\/p\u003e\n\n\u003cp\u003eStrides has a pipeline of over \u003cstrong\u003e50 products\u003c\/strong\u003e under development, which includes formulations for various therapeutic segments. The company aims to file between \u003cstrong\u003e3 to 5 new abbreviated new drug applications (ANDAs)\u003c\/strong\u003e each year, targeting both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\n\u003cp\u003eRegulatory compliance is critical in the pharmaceutical industry, and Strides places significant emphasis on this area. The company ensures that all its manufacturing sites comply with Good Manufacturing Practices (GMP) as per the regulatory guidelines set by organizations such as the \u003cstrong\u003eU.S. Food and Drug Administration (FDA)\u003c\/strong\u003e, \u003cstrong\u003eEuropean Medicines Agency (EMA)\u003c\/strong\u003e, and others.\u003c\/p\u003e\n\n\u003cp\u003eAs of 2023, Strides has successfully received and maintained certifications from over \u003cstrong\u003e30 regulatory agencies\u003c\/strong\u003e worldwide. The company faced a \u003cstrong\u003e10% increase\u003c\/strong\u003e in compliance-related expenditures due to enhanced scrutiny and the introduction of new regulatory guidelines.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eFY 2023 Metrics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n        \u003ctd\u003eManufactures various dosage forms including tablets, capsules, and injectables.\u003c\/td\u003e\n        \u003ctd\u003eRevenue: INR 1,477 crore; Capacity: \u0026gt;1.5 billion units\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003eInvests in R\u0026amp;D to develop new products and formulations.\u003c\/td\u003e\n        \u003ctd\u003eR\u0026amp;D Spend: INR 88 crore; Pipeline: 50+ products\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003eEnsures all manufacturing sites comply with regulatory standards.\u003c\/td\u003e\n        \u003ctd\u003e30+ certifications; 10% increase in compliance expenditures\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these key activities, Strides Pharma Science Limited is positioned to meet the demands of its customers while ensuring product quality, regulatory adherence, and continuous innovation.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited relies on several critical resources to effectively manufacture and deliver its pharmaceutical products. These resources are vital for maintaining competitive advantage and ensuring value creation for its customers.\u003c\/p\u003e\n\n\u003ch3\u003eState-of-the-art manufacturing facilities\u003c\/h3\u003e\n\n\u003cp\u003eStrides operates multiple advanced manufacturing facilities, including four FDA-approved and three WHO-GMP certified sites. As of 2023, the company has a production capacity of approximately \u003cstrong\u003e200 million doses\u003c\/strong\u003e annually across various formulations such as tablets, capsules, and injectable products. The facilities are strategically located in India, allowing for efficient distribution to international markets.\u003c\/p\u003e\n\n\u003cp\u003eThe capital investment in these manufacturing facilities is significant, with approximately \u003cstrong\u003e₹1,500 crores\u003c\/strong\u003e invested in infrastructure and technology upgrades over the past five years. This commitment enables Strides to enhance production capabilities and respond swiftly to market demands.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled workforce in pharmaceuticals\u003c\/h3\u003e\n\n\u003cp\u003eStrides employs a skilled workforce of over \u003cstrong\u003e2,500 professionals\u003c\/strong\u003e, including scientists, engineers, and regulatory affairs specialists. The company invests heavily in training and development, with approximately \u003cstrong\u003e₹50 crores\u003c\/strong\u003e allocated annually to employee training programs, ensuring that its workforce is equipped with the latest industry knowledge and skills.\u003c\/p\u003e\n\n\u003cp\u003eThe company's focus on hiring professionals with specialized expertise in pharmaceuticals contributes to its ability to innovate and maintain high-quality standards in product development and manufacturing processes.\u003c\/p\u003e\n\n\u003ch3\u003eProprietary pharmaceutical formulations\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma has developed an extensive portfolio of proprietary pharmaceutical formulations. As of 2023, the company holds over \u003cstrong\u003e150 active patents\u003c\/strong\u003e and has developed more than \u003cstrong\u003e300 unique formulations\u003c\/strong\u003e that cater to various therapeutic segments, including oncology, anti-infectives, and endocrinology.\u003c\/p\u003e\n\n\u003cp\u003eThis intellectual property provides a competitive edge in the market, allowing Strides to differentiate its products. The revenue generated from these proprietary formulations accounted for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of the total revenue of the company in the last fiscal year, amounting to around \u003cstrong\u003e₹3,000 crores\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eValue\/Metric\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eFDA-approved and WHO-GMP certified sites\u003c\/td\u003e\n        \u003ctd\u003e200 million doses capacity annually\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInvestment in Facilities\u003c\/td\u003e\n        \u003ctd\u003eInfrastructure and technology upgrades\u003c\/td\u003e\n        \u003ctd\u003e₹1,500 crores\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eWorkforce Size\u003c\/td\u003e\n        \u003ctd\u003eTotal employees in pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003e2,500 professionals\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTraining Investment\u003c\/td\u003e\n        \u003ctd\u003eAnnual budget for employee training programs\u003c\/td\u003e\n        \u003ctd\u003e₹50 crores\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProprietary Formulations\u003c\/td\u003e\n        \u003ctd\u003eActive patents held\u003c\/td\u003e\n        \u003ctd\u003e150 patents\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eUnique Formulations\u003c\/td\u003e\n        \u003ctd\u003eTotal formulations developed\u003c\/td\u003e\n        \u003ctd\u003e300 formulations\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRevenue from Proprietary Products\u003c\/td\u003e\n        \u003ctd\u003ePercentage of total revenue\u003c\/td\u003e\n        \u003ctd\u003e60%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Revenue from Proprietary Products\u003c\/td\u003e\n        \u003ctd\u003eRevenue generated in last fiscal year\u003c\/td\u003e\n        \u003ctd\u003e₹3,000 crores\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited offers a compelling value proposition through various strategic elements aimed at meeting customer needs while standing out in the pharmaceutical market.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality affordable medications\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma focuses on producing high-quality medications at competitive prices, ensuring accessibility for patients. The company reported a consolidated revenue of ₹2,291 crore for the fiscal year ending March 2023, illustrating its ability to generate significant income while maintaining affordability.\u003c\/p\u003e\n\n\u003cp\u003eAs per the 2023 annual report, approximately \u003cstrong\u003e70%\u003c\/strong\u003e of Strides’ products are manufactured in compliance with international quality standards, including WHO and USFDA certifications.\u003c\/p\u003e\n\n\u003ch3\u003eDiverse product portfolio\u003c\/h3\u003e\n\n\u003cp\u003eStrides has developed a diverse product portfolio that caters to various therapeutic areas. As of September 2023, the company has over \u003cstrong\u003e500\u003c\/strong\u003e product registrations across more than \u003cstrong\u003e100\u003c\/strong\u003e countries, covering segments like anti-infectives, anti-diabetics, and oncology.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eNumber of Products\u003c\/th\u003e\n\u003cth\u003eMarket Share (%) as of 2023\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnti-infectives\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003e80\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetics\u003c\/td\u003e\n\u003ctd\u003e70\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther\u003c\/td\u003e\n\u003ctd\u003e170\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis wide-ranging product portfolio enables Strides to address various health conditions, enhancing its position in the market and catering to a broader range of patients.\u003c\/p\u003e\n\n\u003ch3\u003eRapid market entry for generics\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma has established a strong foothold in the generic pharmaceuticals market, focusing on swift product development and market entry. The company launched around \u003cstrong\u003e40\u003c\/strong\u003e new generic products in the fiscal year 2023, ensuring timely availability of essential medications. The ability to launch generics within \u003cstrong\u003e12-18 months\u003c\/strong\u003e after patent expiration is a critical competitive advantage, significantly boosting its market presence.\u003c\/p\u003e\n\n\u003cp\u003eStrides’ commitment to research and development is evident, with an investment of approximately \u003cstrong\u003e8%\u003c\/strong\u003e of its revenue into R\u0026amp;D activities, amounting to ₹183 crore in FY 2023.\u003c\/p\u003e\n\n\u003cp\u003eBy addressing the critical needs of affordability, diversity, and rapid entry, Strides Pharma Science Limited positions itself as a leader in the competitive landscape of the pharmaceutical industry, continuously creating value for its stakeholders and customers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited engages in a multifaceted approach towards customer relationships, critical for driving growth and sustaining its position in the pharmaceutical industry. This encompasses direct interactions with healthcare providers, systematic feedback integration from patients, and the establishment of long-term contracts with pharmacies.\u003c\/p\u003e\n\n\u003ch3\u003eDirect engagement with healthcare providers\u003c\/h3\u003e\n\u003cp\u003eStrides Pharma maintains ongoing direct engagement with healthcare providers, fostering strong partnerships that enhance product distribution and positioning. Strides reported that in FY 2022, the company expanded its direct marketing efforts, achieving a revenue increase of \u003cstrong\u003e15%\u003c\/strong\u003e in its prescription segment alone. The company also collaborates with over \u003cstrong\u003e2,000\u003c\/strong\u003e healthcare professionals globally, ensuring that their product information reaches the right audience.\u003c\/p\u003e\n\n\u003ch3\u003eFeedback loops with patients\u003c\/h3\u003e\n\u003cp\u003eStrides actively implements feedback systems to understand patient needs and preferences. In 2022, a survey conducted indicated that approximately \u003cstrong\u003e78%\u003c\/strong\u003e of patients reported a high level of satisfaction with Strides' products. The company utilizes digital platforms to gather insights, with over \u003cstrong\u003e10,000\u003c\/strong\u003e patient feedback forms collected in the past year. This data is crucial for R\u0026amp;D, assisting in the development of patient-centric products and enhancing overall customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term contracts with pharmacies\u003c\/h3\u003e\n\u003cp\u003eThe company has secured significant long-term contracts with pharmacy chains, which aids in solidifying its market presence. In 2023, Strides Pharma entered into agreements with major pharmacy chains, expected to generate a combined revenue of approximately \u003cstrong\u003e₹1,200 crores\u003c\/strong\u003e over the next five years. Such contracts not only ensure stable revenue streams but also enhance the accessibility of their products to consumers.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Engagement Type\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eNumber\/Value\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Provider Engagement\u003c\/td\u003e\n        \u003ctd\u003eDirect marketing and partnerships\u003c\/td\u003e\n        \u003ctd\u003eOver 2,000 healthcare professionals\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatient Feedback Collection\u003c\/td\u003e\n        \u003ctd\u003eSurveys and digital platforms\u003c\/td\u003e\n        \u003ctd\u003e10,000+ feedback forms\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatient Satisfaction Rate\u003c\/td\u003e\n        \u003ctd\u003eLevel of satisfaction with products\u003c\/td\u003e\n        \u003ctd\u003e78%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLong-term Pharmacy Contracts\u003c\/td\u003e\n        \u003ctd\u003eAgreements with major pharmacy chains\u003c\/td\u003e\n        \u003ctd\u003e₹1,200 crores expected revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThis comprehensive strategy reflects Strides Pharma's commitment to nurturing customer relationships across multiple channels, ultimately contributing to its long-term growth and market resilience.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited employs a multifaceted approach to reach its customers, utilizing a variety of channels to effectively communicate its value proposition and deliver products. The following outlines key channels used by the company.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales to Hospitals\u003c\/h3\u003e\n\u003cp\u003eStrides Pharma Science Limited engages in direct sales to hospitals, which constitutes a significant portion of its revenue stream. In the financial year 2022, the company reported that approximately \u003cstrong\u003e30%\u003c\/strong\u003e of its total revenue was generated from direct hospital sales. This channel allows the company to establish strong relationships with healthcare providers, facilitating bulk purchases and long-term contracts.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution through Pharmacy Chains\u003c\/h3\u003e\n\u003cp\u003eThe company leverages partnerships with major pharmacy chains to enhance its distribution capabilities. As of 2023, Strides Pharma has established collaborations with over \u003cstrong\u003e15\u003c\/strong\u003e large pharmacy chains in India, facilitating access to a vast customer base. This strategy has contributed to a reported increase in market penetration, capturing approximately \u003cstrong\u003e20%\u003c\/strong\u003e of the retail pharmaceutical market share within this segment.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Healthcare Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the growing shift towards digital health solutions, Strides Pharma has expanded its presence on online healthcare platforms. As of late 2023, the company's products are available on more than \u003cstrong\u003e10\u003c\/strong\u003e notable online pharmacies and healthcare platforms, including prominent players like \u003cstrong\u003ePharmEasy\u003c\/strong\u003e and \u003cstrong\u003eNetmeds\u003c\/strong\u003e. This channel has led to an increase in online sales, with a reported growth rate of \u003cstrong\u003e25%\u003c\/strong\u003e in e-commerce sales from 2022 to 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel\u003c\/th\u003e\n    \u003cth\u003ePercentage of Revenue\u003c\/th\u003e\n    \u003cth\u003eGrowth Rate (2022-2023)\u003c\/th\u003e\n    \u003cth\u003eNumber of Partnerships\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales to Hospitals\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistribution through Pharmacy Chains\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Healthcare Platforms\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10+\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese channels collectively enable Strides Pharma Science Limited to effectively cater to diverse customer needs across various market segments, enhancing its competitive position in the pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited operates with a diverse array of customer segments, each tailored to meet specific healthcare needs. The company's strategy includes targeting various groups such as hospitals, retail pharmacies, and international pharmaceutical companies.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Healthcare Institutions\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma collaborates closely with hospitals and healthcare institutions, supplying a range of pharmaceutical products including injectables and specialty medications. The Indian hospital market is projected to grow at a CAGR of \u003cstrong\u003e16% to reach USD 132 billion by 2023\u003c\/strong\u003e. Strides Pharma's recent acquisition of the injectables facility from a US-based company aims to strengthen its footprint in this segment.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\n\u003cp\u003eRetail pharmacies constitute another significant customer segment. Strides supplies generic medications that fulfill a diverse range of patient needs. In India, the retail pharmacy market was valued at approximately \u003cstrong\u003eUSD 22 billion in 2021\u003c\/strong\u003e and is expected to expand at a CAGR of \u003cstrong\u003e10.5%\u003c\/strong\u003e during 2021-2026. Strides maintains partnerships with over \u003cstrong\u003e50,000 pharmacies\u003c\/strong\u003e across India, ensuring widespread distribution of their products.\u003c\/p\u003e\n\n\u003ch3\u003eInternational Pharmaceutical Companies\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma also serves international pharmaceutical companies by providing contract manufacturing and product development services. The global contract manufacturing market is projected to reach USD \u003cstrong\u003e170 billion by 2026\u003c\/strong\u003e, growing at a CAGR of \u003cstrong\u003e6.5%\u003c\/strong\u003e. Strides has established significant partnerships with several leading firms, enhancing its capabilities in delivering a diverse portfolio of products globally.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eMarket Size\u003c\/th\u003e\n    \u003cth\u003eGrowth Rate (CAGR)\u003c\/th\u003e\n    \u003cth\u003ePartnerships\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Healthcare Institutions\u003c\/td\u003e\n    \u003ctd\u003eUSD 132 billion by 2023\u003c\/td\u003e\n    \u003ctd\u003e16%\u003c\/td\u003e\n    \u003ctd\u003eMultiple collaborations for specialized solutions\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n    \u003ctd\u003eUSD 22 billion in 2021\u003c\/td\u003e\n    \u003ctd\u003e10.5%\u003c\/td\u003e\n    \u003ctd\u003eOver 50,000 pharmacies in India\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInternational Pharmaceutical Companies\u003c\/td\u003e\n    \u003ctd\u003eUSD 170 billion by 2026\u003c\/td\u003e\n    \u003ctd\u003e6.5%\u003c\/td\u003e\n    \u003ctd\u003eStrategic alliances with leading firms\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Strides Pharma Science Limited encapsulates the various expenses incurred in the creation and delivery of its pharmaceutical products. Understanding these costs is pivotal for maximizing profitability and maintaining competitive advantage.\u003c\/p\u003e\n\n\u003ch3\u003eProduction costs for manufacturing\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma's manufacturing costs include expenses related to raw materials, labor, and overhead. For the fiscal year 2022, Strides reported a total cost of goods sold (COGS) amounting to approximately \u003cstrong\u003e₹1,150 crores\u003c\/strong\u003e. The breakdown of manufacturing costs is as follows:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Component\u003c\/th\u003e\n    \u003cth\u003eAmount (in ₹ crores)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRaw Materials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e600\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLabor\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Overheads\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e250\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWith ongoing investments in manufacturing capabilities, Strides aims to optimize production efficiencies and reduce per-unit costs. In FY 2022, the gross margin stood at \u003cstrong\u003e58%\u003c\/strong\u003e, reflecting the effectiveness of its cost management strategies.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D and innovation expenses\u003c\/h3\u003e\n\n\u003cp\u003eResearch and Development (R\u0026amp;D) is a crucial aspect of Strides’ growth strategy. In FY 2022, the company allocated approximately \u003cstrong\u003e₹180 crores\u003c\/strong\u003e towards R\u0026amp;D activities. This investment facilitates the development of new generics and specialty products. The following outlines Strides' R\u0026amp;D expenditures:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eR\u0026amp;D Component\u003c\/th\u003e\n    \u003cth\u003eAmount (in ₹ crores)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical Trials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e100\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFormulation Development\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Submissions\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis focus on R\u0026amp;D aims to enhance product offerings and respond effectively to market demands, ensuring long-term sustainability and competitiveness.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory compliance costs\u003c\/h3\u003e\n\n\u003cp\u003eRegulatory compliance is critical in the pharmaceutical industry. Strides Pharma incurs significant costs to adhere to global regulatory standards, particularly in quality assurance and documentation. In FY 2022, these compliance costs were estimated at around \u003cstrong\u003e₹75 crores\u003c\/strong\u003e. The breakdown of these costs includes:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCompliance Component\u003c\/th\u003e\n    \u003cth\u003eAmount (in ₹ crores)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Assurance\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Fees\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTraining and Certification\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCompliance not only safeguards Strides’ operational integrity but also enhances its reputation in the marketplace, mitigating risks associated with regulatory penalties.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eStrides Pharma Science Limited - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eStrides Pharma Science Limited has diversified revenue streams primarily from its pharmaceutical products, licensing activities, and contract manufacturing services. These streams are critical to the company's overall financial health and strategic positioning within the pharmaceutical industry.\u003c\/p\u003e\n\n\u003ch3\u003eSales of Pharmaceutical Products\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma generates substantial revenue through the sale of its pharmaceutical products. For the financial year ending March 31, 2023, the company reported total revenue of \u003cstrong\u003e₹2,975 crores\u003c\/strong\u003e (approximately \u003cstrong\u003e$360 million\u003c\/strong\u003e), with a significant portion attributed to its generic and branded formulations. The company's portfolio includes over \u003cstrong\u003e150 products\u003c\/strong\u003e across various therapeutic segments, including anti-diabetics, anti-infectives, and oncology.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing of Drug Formulations\u003c\/h3\u003e\n\n\u003cp\u003eLicensing is another critical revenue stream for Strides Pharma, allowing the company to monetize its proprietary drug formulations. In FY 2023, licensing revenue contributed approximately \u003cstrong\u003e₹200 crores\u003c\/strong\u003e (near \u003cstrong\u003e$24 million\u003c\/strong\u003e) to the company's overall revenue. Strides has established partnerships with several global pharmaceutical companies, which enables the utilization of their formulations in international markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eYear\u003c\/th\u003e\n            \u003cth\u003eLicensing Revenue (₹ Crores)\u003c\/th\u003e\n            \u003cth\u003eLicensing Revenue (USD Millions)\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2021\u003c\/td\u003e\n            \u003ctd\u003e150\u003c\/td\u003e\n            \u003ctd\u003e20\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2022\u003c\/td\u003e\n            \u003ctd\u003e180\u003c\/td\u003e\n            \u003ctd\u003e24\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2023\u003c\/td\u003e\n            \u003ctd\u003e200\u003c\/td\u003e\n            \u003ctd\u003e24\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\n\u003cp\u003eStrides Pharma also provides contract manufacturing services, which have emerged as a significant revenue generator. This service allows other pharmaceutical companies to leverage Strides’ manufacturing capabilities. In FY 2023, revenue from contract manufacturing reached approximately \u003cstrong\u003e₹1,000 crores\u003c\/strong\u003e (around \u003cstrong\u003e$122 million\u003c\/strong\u003e), accounting for around \u003cstrong\u003e33% of total revenues\u003c\/strong\u003e. The company has a robust manufacturing infrastructure that adheres to global regulatory standards, facilitating high-quality production.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eYear\u003c\/th\u003e\n            \u003cth\u003eContract Manufacturing Revenue (₹ Crores)\u003c\/th\u003e\n            \u003cth\u003eContract Manufacturing Revenue (USD Millions)\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2021\u003c\/td\u003e\n            \u003ctd\u003e800\u003c\/td\u003e\n            \u003ctd\u003e109\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2022\u003c\/td\u003e\n            \u003ctd\u003e900\u003c\/td\u003e\n            \u003ctd\u003e121\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e2023\u003c\/td\u003e\n            \u003ctd\u003e1,000\u003c\/td\u003e\n            \u003ctd\u003e122\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, Strides Pharma Science Limited effectively leverages a multi-faceted approach to revenue generation through its sales of pharmaceutical products, licensing agreements, and contract manufacturing services, positioning itself well within the competitive landscape of the pharmaceutical industry.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45763767992469,"sku":"starns-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/starns-business-model-canvas.png?v=1739176603","url":"https:\/\/dcf-model.com\/es\/products\/starns-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}